Beta-blocker therapy in AMI patients with preserved ejection fraction shows comparable outcomes to non-useNew analysis shows beta-blockers do not lower heart attack risks for most patients with strong hearts

This meta-analysis synthesized evidence from randomized controlled trials examining beta-blocker therapy in patients with acute myocardial infarction and a left ventricular ejection fraction of 40% or greater. The analysis included a total population of 19,826 patients. The intervention was beta-blocker therapy, and the comparator was non-beta-blocker therapy. The study design and setting were not specified in detail.

The primary outcome was a composite of all-cause death, myocardial infarction, and hospitalization for heart failure. The main result showed that this outcome was comparable between the two groups. The effect size was a hazard ratio of 0.93, with a 95% confidence interval of 0.82 to 1.04. This indicates that beta-blocker therapy was not significantly associated with lower cardiovascular outcomes.

Key secondary outcomes included hospitalization for a composite of bradycardia, atrioventricular block, and pacemaker implantation, stroke, and each component of the primary outcome. For the safety outcome of hospitalization for bradyarrhythmic events, the result was comparable between groups, with a hazard ratio of 1.06 and a 95% confidence interval of 0.83 to 1.34. This indicates that beta-blocker therapy was not significantly associated with higher bradyarrhythmic events.

Safety and tolerability findings were detailed for the composite bradyarrhythmic outcome. The analysis reported hospitalization for this composite as the adverse event measure. No specific rates of serious adverse events, discontinuations, or overall tolerability were reported.

These results can be compared to prior landmark studies in this therapeutic area, though specific comparisons were not reported in the input. The findings suggest a potential shift in practice, as earlier guidelines often recommended beta-blockers for most AMI patients.

Key methodological limitations include that further trials are warranted to clarify the role and necessity of beta-blockers. The analysis did not report details on study settings, follow-up periods, or specific trial characteristics, which may introduce potential biases.

Clinical implications are that for patients with AMI and preserved ejection fraction, beta-blocker therapy may not provide additional benefit over non-use for the composite cardiovascular outcome. Practice decisions should consider this evidence, though individual patient factors remain important.

Questions that remain unanswered include the optimal duration of therapy, specific patient subgroups that might benefit, and the long-term effects of beta-blocker use in this population.